Search Result

Results for "

Sprague-Dawley rat

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Amino Acid Derivatives (1) Aminopeptidase (1) Apoptosis (1) Biochemical Assay Reagents (1) COX (1) Dopamine Receptor (1) GABA Receptor (1) GlyT (1) GnRH Receptor (2) Guanylate Cyclase (1) Histamine Receptor (1) Interleukin Related (1) JNK (1) nAChR (1) Neurotensin Receptor (1) NO Synthase (1) PD-1/PD-L1 (1) PPAR (1) Protease Activated Receptor (PAR) (1) Ras (1) Sigma Receptor (1) Sodium Channel (1) Somatostatin Receptor (2) STAT (1) Toll-like Receptor (TLR) (1) TRP Channel (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (5) Endocrinology (1) Inflammation/Immunology (10) Metabolic Disease (4) Neurological Disease (12)

By Targets:

5-HT Receptor (1)

Adrenergic Receptor (1)

Amino Acid Derivatives (1)

Aminopeptidase (1)

Apoptosis (1)

Biochemical Assay Reagents (1)

COX (1)

Dopamine Receptor (1)

GABA Receptor (1)

GlyT (1)

GnRH Receptor (2)

Guanylate Cyclase (1)

Histamine Receptor (1)

Interleukin Related (1)

JNK (1)

nAChR (1)

Neurotensin Receptor (1)

NO Synthase (1)

PD-1/PD-L1 (1)

PPAR (1)

Protease Activated Receptor (PAR) (1)

Ras (1)

Sigma Receptor (1)

Sodium Channel (1)

Somatostatin Receptor (2)

STAT (1)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (5)

Endocrinology (1)

Inflammation/Immunology (10)

Metabolic Disease (4)

Neurological Disease (12)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5875A

P4pal10 TFA	Protease Activated Receptor (PAR)	Cardiovascular Disease Inflammation/Immunology
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .

HY-159062

Goji Extract	Biochemical Assay Reagents NO Synthase	Neurological Disease
Goji Extract is a natural product with anti-aging, antioxidant, and neuroprotective effects. The antioxidant effect of Goji Extract has a positive impact on erectile dysfunction and can be used in research to improve erectile function .

HY-N11925

(+)-Osbeckic acid	Others	Cardiovascular Disease
(+)-Osbeckic acid is a vasorelaxatant that can be isolated from Tartary Buckwheat. (+)-Osbeckic acid has a potent vasorelaxant effect in Sprague-Dawley rat thoracic aorta rings with an EC₅₀ of 887 μM .

HY-151360

NHE3-IN-3	Sodium Channel	Metabolic Disease
NHE3-IN-3 (Compound 1) is a Na ⁺/H ⁺ exchanger isoform 3 (NHE3) inhibitor with pIC₅₀ of 6.2 and 6.6 against human and rat NHE3, respectively. NHE3-IN-3 shows high (98%) oral bioavailability in Sprague–Dawley rats .

HY-N2196

Ajugasterone C	Others	Inflammation/Immunology
Ajugasterone C is an ecdysteroid isolated from Leuzea carthamoides. Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to Carrageenan-induced inflammation in Sprague Dawley rats .

HY-121123

Adamantanine 2-Aminoadamantane-2-carboxylic acid	Aminopeptidase	Cancer
Adamantanine (2-Aminoadamantane-2-carboxylic acid) inhibits the transport of methionine (K_i is 0.76 mM) and leucine into Ehrlich ascites carcinoma cells. Adamantanine inhibits proliferation of P388 lymphocytic leukemia cells with an IC₅₀ of >1 mM. Adamantanine inhibits the leucine aminopeptidase with an I/S_0.5 of 10.5 .

HY-117443

IWP-051	Guanylate Cyclase	Cardiovascular Disease
IWP-051 is an agonist for soluble guanylate cyclase with an EC₅₀ of 290 nM. IWP-051 stimulates the generation of cGMP, and exhibits the synergistic effect with NO. IWP-051 exhibits good pharmacokinetic characteristics in rats .

HY-127125

Diclofenac ethyl ester	COX	Inflammation/Immunology
Diclofenac ethyl ester is the prodrug of Diclofenac (HY-15036), that is encapsulated in polymer micelles in vitro, and released with prolonged circulation time and reduced drug concentrations in the heart and kidneys in vivo .

HY-P1134

Galanin (1-15) (porcine, rat)	5-HT Receptor	Neurological Disease
Galanin (1-15) (porcine, rat) is the N-terminal 15 amino acids peptide fragment of the neuropeptide galanin. Galanin (1-15) (porcine, rat) interacts with the 5-HT1A receptor in the dorsal hippocampus of the rat brain, reduces the affinity of 5-HT1A receptors, and regulates the serotonin neuronal networks .

HY-161784

GABAA receptor modular-3	GABA Receptor	Neurological Disease
GABAA receptor modular-3 (Compound S28) is a modulator for (γ-aminobutyric acid)A receptor (GABAA receptor), with EC₅₀ of 56 nM and 10 nM, for α1β2γ2 and α4β3δ subtype. GABAA receptor modular-3 exhibits good pharmacokinetic characteristics in rats. GABAA receptor modular-3 is slightly toxic toxicity in rats with a loss of rollover reflex (LORR) threshold dose of 23.3 μmol/kg, and exhibits potential ameliorating the postpartum depression .

HY-120287

L-054522	Somatostatin Receptor	Endocrinology
L-054522 is an agonist for somatostatin receptor subtype 2 with K_d of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC₅₀=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC₅₀=0.05 nM and 12 nM) .

HY-163998

TLR4-IN-1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR4-IN-1 (compound 3k) inhibits the cell viability of RAW264.7 with an IC₅₀ of 1.02 μM. TLR4-IN-1 inhibits the release of cytokine TNF-α, IL-1β and IL-6, and exhibits anti-inflammatory efficacy in rats rheumatoid arthritis models .

HY-P10767

MD01-67	Neurotensin Receptor	Neurological Disease
MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with K_i of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models .

HY-B1258

4-(Aminomethyl)benzoic acid Aminomethylbenzoic acid; α-Amino-p-toluic acid	Amino Acid Derivatives	Cancer
4-(Aminomethyl)benzoic acid is a competitive inhibitor of PepT1 and has antifibrinolytic activity .

HY-161925

sTGFBR3 antagonist 1	Others	Neurological Disease Inflammation/Immunology
sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC₅₀ of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research .

HY-168068

Res-Glu3	Others	Neurological Disease
Res-Glu3 is the derivative of Resveratrol (HY-16561). Res-Glu3 mitigates the ROS accumulation, and exhibits neuroprotective efficacy against H₂O₂-caused cellular damage in PC12. Res-Glu3 exhibits antioxidant activity in rats ischemia reperfusion models .

HY-162963

PPARδ agonist 11	PPAR	Inflammation/Immunology
PPARδ agonist 11 (Compound 11) is a selective agonist for PPARδ with an EC₅₀ of 20 nM. PPARδ agonist 11 reduces the levels of nitrite oxide (NO), proinflammatory cytokines TNFα and IL-6 in LPS (HY-D1056)-stimulated RAW264.7 cell, and exhibits anti-inflammatory efficacy via NF-κB pathway. PPARδ agonist 11 exhibits good stability in human liver microsomes and plasma. PPARδ agonist 11 ameliorates Carrageenan (HY-125474)-induced foot edema .

HY-10716A

PF-03463275	GlyT	Neurological Disease
PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a K_i of 11.6 nM. PF-03463275 has the potential for Schizophrenia research .

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-19590

Etarotene Ro 15-1570	Others	Cancer
Etarotene (Ro 15-1570) is a derivative of Arotinoid (HY-106735). Etarotene is an orally active antitumor agent against DMBA (HY-W011845)-induced mammary tumor and causes toxic symptoms of hypervitaminosis A in rat model .

HY-151066

BMS-1233	PD-1/PD-L1	Cancer
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC₅₀ of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .

HY-160959

AN317	nAChR	Neurological Disease
AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with K_i of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP ⁺. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .

HY-160023

D3S-001	Ras	Cancer
D3S-001 is an orally active inhibitor for KRAS. D3S-001 inhibits the proliferation of KRAS ^G12C mutant H358 and MIA-PA-CA-2 with an IC₅₀ of 0.6 and 0.44 nM. D3S-001 exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice .

HY-120476

JNJ-39729209	TRP Channel	Neurological Disease Inflammation/Immunology
JNJ-39729209 is an antagonist for transient receptor potential vanilloid 1 (TRPV1) with pIC₅₀ of 7.9, 8.5, 7.9 and 7.7 for TRPV1 from human, rat, canine and guinea pig. JNJ-39729209 inhibits Capsaicin (HY-10448)-induced hypotension and inhibit thereby hypothermia. JNJ-39729209 exhibits anti-inflammatory and analgesic activities in Carrageenan (HY-125474)- and CFA (HY-153808)-induced thermal hyperalgesia rat models. JNJ-39729209 exhibits anti-cough effects in guinea pigs .

HY-164320

Anticancer agent 245	Others	Cancer
Anticancer agent 245 (Compound 115) inhibits proliferation of cancer cell SKOV3, MDA-MB-231 and HCT-116 with IC₅₀ of 0.021, 0.056 and 0.11 μM, respectively. Anticancer agent 245 exhibits antitumor efficacy in mice and good pharmacokinetic characteristics in rat models .

HY-169177

JNK-1-IN-4	JNK	Inflammation/Immunology
JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC₅₀s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .

HY-161705

Anti-apoptotic agent 1	Apoptosis	Neurological Disease
Anti-apoptotic agent 1 (Compound B4) exhibits neuroprotective activity and good pharmacokinetic properties. Anti-apoptotic agent 1 inhibits apoptosis, prevents stroke recurrence in photothrombotic rat model .

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-P3641

Kisspeptin 13	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-P3641A

Kisspeptin 13 TFA	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-164010

SUN-1334H free base	Histamine Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor	Cardiovascular Disease Inflammation/Immunology
SUN-1334H free base is an orally active inhibitor for histamine H1 receptor, with an IC₅₀ of 20.3 nM and K_i of 9.7 nM. SUN-1334H free base inhibits histamine-induced contractions of isolated guinea-pig ileum with an IC₅₀ of 0.198 μM. SUN-1334H free base inhibits histamine-induced bronchoconstriction in guinea pigs, histamine-induced skin wheals in beagle dogs, and ovalbumin-induced rhinitis in guinea pigs .

Cat. No.	Product Name	Type